These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11890253)

  • 21. Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer.
    Hrouda D; Todryk SM; Perry MJ; Souberbielle BE; Kayaga J; Kirby RS; Dalgleish AG
    BJU Int; 2000 Oct; 86(6):742-8. PubMed ID: 11069388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer cell motility-inhibitory protein in the Dunning adenocarcinoma model.
    Mohler JL; Broskie EN; Ranparia DJ; Sharief Y; Coleman WB; Smith GJ
    Cancer Res; 1992 Apr; 52(8):2349-52. PubMed ID: 1559238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of castanospermine on the metastatic properties of prostate cancer cells.
    Yee CS; Schwab ED; Lehr JE; Quigley M; Pienta KJ
    Anticancer Res; 1997; 17(5A):3659-63. PubMed ID: 9413219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated expression of calcium-binding protein p9Ka is associated with increasing malignant characteristics of rat prostate carcinoma cells.
    Ke Y; Jing C; Barraclough R; Smith P; Davies MP; Foster CS
    Int J Cancer; 1997 May; 71(5):832-7. PubMed ID: 9180153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oleuropein: A Potential Inhibitor for Prostate Cancer Cell Motility by Blocking Voltage-Gated Sodium Channels.
    Aktas HG; Ayan H
    Nutr Cancer; 2021; 73(9):1758-1767. PubMed ID: 32842786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contact guidance of Walker carcinosarcoma cells by the underlying normal fibroblasts is inhibited by RGD-containing synthetic peptides.
    Madeja Z; Sroka J
    Folia Histochem Cytobiol; 2002; 40(3):251-60. PubMed ID: 12219835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Promotion of metastases by tumor necrosis factor in rats bearing Dunning R3327 MAT-LyLu prostatic cancer.
    Iizumi T; Yazaki T; Umeda T; Soma GI
    Urol Int; 1993; 51(2):85-8. PubMed ID: 8351760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of candidates for cancer cell motility inhibitory protein in the Dunning adenocarcinoma model.
    Mohler JL; Bakewell WE; Sharief Y; Coleman WB; Chay CH; Silvers SM; Smith GJ
    Clin Exp Metastasis; 1995 Nov; 13(6):474-80. PubMed ID: 7586805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell motility affects the intensity of gap junctional coupling in prostate carcinoma and melanoma cell populations.
    Daniel-Wójcik A; Misztal K; Bechyne I; Sroka J; Miekus K; Madeja Z; Czyz J
    Int J Oncol; 2008 Aug; 33(2):309-15. PubMed ID: 18636151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of metastatic potential by cancer cell motility in the Dunning R-3327 prostatic adenocarcinoma in vivo model.
    Doyle GM; Sharief Y; Mohler JL
    J Urol; 1992 Feb; 147(2):514-8. PubMed ID: 1732634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morpho-physiological heterogeneity of cells within two rat prostate carcinoma cell lines AT-2 and MAT-LyLu differing in the degree of malignancy observed by cell cloning and the effects of caffeine, theophylline and papaverine upon a proportion of the clones.
    Musialik E; Ryszawy D; Madeja Z; Korohoda W
    Oncol Rep; 2013 May; 29(5):1789-96. PubMed ID: 23467722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells.
    Haq M; Goltzman D; Tremblay G; Brodt P
    Cancer Res; 1992 Sep; 52(17):4613-9. PubMed ID: 1511429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor.
    Isaacs JT; Yu GW; Coffey DS
    Invest Urol; 1981 Jul; 19(1):20-3. PubMed ID: 7251319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Establishment and in vivo characterization of multidrug-resistant dunning R3327 rat prostate-carcinoma cell-lines.
    Bashir I; Sikora K; Abel P; Foster CS
    Int J Cancer; 1994 Jun; 57(5):719-26. PubMed ID: 7910810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topographical control of prostate cancer cell migration.
    Sarna M; Wybieralska E; Miekus K; Drukala J; Madeja Z
    Mol Med Rep; 2009; 2(5):865-71. PubMed ID: 21475914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour-stroma interactions between metastatic prostate cancer cells and fibroblasts.
    Kaminski A; Hahne JC; Haddouti el-M; Florin A; Wellmann A; Wernert N
    Int J Mol Med; 2006 Nov; 18(5):941-50. PubMed ID: 17016625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electrophysiological characterization of voltage-gated Na+ current expressed in the highly metastatic Mat-LyLu cell line of rat prostate cancer.
    Grimes JA; Djamgoz MB
    J Cell Physiol; 1998 Apr; 175(1):50-8. PubMed ID: 9491780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of
    Gumushan-Aktas H; Altun S
    Oncol Lett; 2016 Oct; 12(4):2985-2991. PubMed ID: 27698887
    [No Abstract]   [Full Text] [Related]  

  • 39. Expression profiles of voltage-gated Na(+) channel alpha-subunit genes in rat and human prostate cancer cell lines.
    Diss JK; Archer SN; Hirano J; Fraser SP; Djamgoz MB
    Prostate; 2001 Aug; 48(3):165-78. PubMed ID: 11494332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single cell adhesion measuring apparatus (SCAMA): application to cancer cell lines of different metastatic potential and voltage-gated Na+ channel expression.
    Palmer CP; Mycielska ME; Burcu H; Osman K; Collins T; Beckerman R; Perrett R; Johnson H; Aydar E; Djamgoz MB
    Eur Biophys J; 2008 Apr; 37(4):359-68. PubMed ID: 17879092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.